[Expression of aFGF in ovarian epithelial cancer and its signal transduction pathway].
OBJECTIVE
To explore the expression of acidic fibroblast growth factor (aFGF) and its receptor FGFR1 in ovarian epithelial cancer and observe the effects of aFGF and TPK inhibitor Genistein on intracellular PKC and ERK activity in ovarian epithelial cancer cells line CAOV3.


METHODS
The expression levels of aFGF and FGFR1 were evaluated by RT-PCR and western blot in 40 cases of ovarian epithelial cancer. The activity of PKC and ERK in cells induced by different concentration of aFGF and Genistein were detected by incorporation of [gamma-(32)P]-ATP into exogenous substrate.


RESULTS
The expression levels of aFGFmRNA and FGFR1mRNA in the ovarian epithelial cancer were 0.981 +/- 0.130 and 1.047 +/- 0.148, respectively. Compared with normal ovary, ovarian tumor like condition and benign ovary tumors, the difference was significant (P < 0.05). The expression levels in stage III - IV were significantly higher than those in stage I - II (P < 0.05). There were overexpression of aFGF and FGFR1 in the ovarian epithelial cancer in western blot, too. The intracellular PKC and ERK activity increased with aFGF in a dose dependent manner, Genistein suppressed the intracellular PKC and ERK activity also in a dose dependent manner.


CONCLUSIONS
aFGF may play an important role in carcinogenesis, development and invasion of ovarian epithelial cancer. Its receptor in human ovarian cancer cell line CAOV3 possessed TPK activity. These tyrosine-specific protein phosphorylation may initiate a cascade of biochemical events, which may increase the intracellular PKC and ERK activity. PKC and ERK locate downstream of TPK in CAOV3 cell line.
Zhang
Yi
Y
Department of Gynecology, First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Sun
Li-guang
LG
Shang
Hai
H
Gao
Hong
H
Yu
Hui-ying
HY
Gao
Shu-mei
SM
Liu
Ning
N
D000328:Adult; D000368:Aged; D015153:Blotting, Western; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D019833:Genistein / Q000494:pharmacology; D006801:Humans; D008875:Middle Aged; D020928:Mitogen-Activated Protein Kinases / Q000502:physiology; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D011493:Protein Kinase C / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis / Q000235:genetics; D051496:Receptor, Fibroblast Growth Factor, Type 1; D017468:Receptors, Fibroblast Growth Factor / Q000032:analysis / Q000235:genetics; D015398:Signal Transduction / Q000502:physiology*
D012333:RNA, Messenger; D017468:Receptors, Fibroblast Growth Factor; D016220:Fibroblast Growth Factor 1; D019833:Genistein; C496348:FGFR1 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051496:Receptor, Fibroblast Growth Factor, Type 1; D011493:Protein Kinase C; D020928:Mitogen-Activated Protein Kinases